DC-based immunotherapy to treat Malignant Mesothelioma

Veröffentlichungen

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial

Autoren: Robert A. Belderbos, Paul Baas, Rossana Berardi, Robin Cornelissen, Dean A. Fennell, Jan P. van Meerbeeck, Arnaud Scherpereel, Heleen Vroman, Joachim G. J. V. Aerts
Veröffentlicht in: Translational Lung Cancer Research, Issue 8/3, 2019, Page(s) 280-285, ISSN 2218-6751
Herausgeber: AME publishing company
DOI: 10.21037/tlcr.2019.05.05

Rechte des geistigen Eigentums

METHOD FOR PREPARING AN IMMUNOGENIC LYSATE, THE LYSATE OBTAINED, DENDRITIC CELLS LOADED WITH SUCH LYSATE AND A PHARMACEUTICAL COMPOSITION COMPRISING THE LYSATE OR THE DENDRITIC CELLS

Antrags-/Publikationsnummer: EP 13821476
Datum: 2013-12-20
Antragsteller: AMPHERA BV

METHOD FOR PREPARING AN IMMUNOGENIC LYSATE, THE LYSATE OBTAINED, DENDRITIC CELLS LOADED WITH SUCH LYSATE AND A PHARMACEUTICAL COMPOSITION COMPRISING THE LYSATE OR THE DENDRITIC CELLS

Antrags-/Publikationsnummer: EP 13821476
Datum: 2013-12-20
Antragsteller: AMPHERA BV

Pharmaceutical composition for use in the treatment of cancer

Antrags-/Publikationsnummer: PCT/NL2017/ 050809
Datum: 2016-12-02
Antragsteller: AMPHERA BV